Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NVCR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovoCure receives CE Mark for Optune Pax in pancreatic cancer, enabling European launch
Filed June 30, 2026 · Period ending June 30, 2026 · ~1 min read
Key Changes
-
high
Optune Pax received CE Mark approval for locally advanced pancreatic cancer in Europe, enabling commercial launch in Germany within weeks following February 2026 FDA approval in the U.S.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
high
Phase 3 PANOVA-3 trial met primary endpoint: patients using Optune Pax with chemotherapy achieved median survival of 16.2 months versus 14.2 months for chemotherapy alone (2-month improvement, HR 0.82, p=0.039).
Exhibit 99.1 view on EDGAR → -
medium
Trial showed 6.1-month delay in pain progression (15.2 vs 9.1 months, HR 0.74, p=0.027), addressing a debilitating symptom in pancreatic cancer patients.
Exhibit 99.1 view on EDGAR → -
medium
Device was well-tolerated with no new safety signals; 76.3% experienced mild-to-moderate skin reactions under arrays, only 7.7% had severe skin events, and serious adverse events matched chemotherapy-alone arm.
Exhibit 99.1 view on EDGAR →
Summary
NovoCure announced CE Mark approval for Optune Pax to treat locally advanced pancreatic cancer in Europe, expanding the device's commercial footprint four months after U.S. FDA approval. The wearable device delivers alternating electric fields that disrupt cancer cell division and is used alongside standard gemcitabine/nab-paclitaxel chemotherapy.
The company plans to launch in Germany within weeks, entering a European market with approximately 146,000 annual pancreatic cancer diagnoses. The approval is supported by the Phase 3 PANOVA-3 trial, which enrolled 571 patients and demonstrated a statistically significant 2-month survival improvement (16.2 vs 14.2 months median overall survival).
The trial also showed a 6.1-month delay in pain progression, a meaningful quality-of-life benefit in a cancer type known for debilitating symptoms. The device was well-tolerated with no new safety concerns beyond expected mild-to-moderate skin reactions in most patients. For investors, this represents geographic expansion of a recently approved product into a significant market. The survival and pain-control data strengthen the clinical value proposition beyond the U.S. launch, though commercial uptake will depend on reimbursement negotiations, physician adoption, and patient compliance with the wearable device in real-world settings.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.
NovoCure received European regulatory approval (CE Mark) for its wearable Optune Pax device to treat locally advanced pancreatic cancer when used alongside standard chemotherapy. This approval allows the company to market and sell the device in Europe, with a planned launch in Germany in the coming weeks. The device delivers alternating electric fields that disrupt cancer cell division.
Added in current filing · view on EDGAR →
Patients treated with Optune Pax concomitant with gem/nab-pac had a median time to pain progression of 15.2 months (95% CI 10.3–22.8) compared to a median 9.1 months in the group treated with gem/nab-pac alone (95% CI 7.4–12.7). This is a significant 6.1-month extension in time to pain progression [HR 0.74; (95% CI 0.56–0.97) p=0.027].
The trial showed Optune Pax significantly delayed pain progression by 6.1 months compared to chemotherapy alone. Pain is a debilitating symptom of pancreatic cancer, and this delay helps preserve quality of life. This secondary endpoint strengthens the clinical value proposition beyond survival alone.
Added in current filing · view on EDGAR →
Optune Pax was approved by the U.S. Food and Drug Administration in February 2026. Novocure plans to launch Optune Pax in Germany in the coming weeks.
The device already received U.S. FDA approval in February 2026, and the company is now expanding into Europe with an imminent launch in Germany. This represents geographic expansion of a recently approved product into a market with approximately 146,000 pancreatic cancer diagnoses annually.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Optune Pax® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with locally-advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.
NovoCure announced that its Optune Pax device received CE Mark approval in Europe for treating locally-advanced pancreatic cancer when used alongside gemcitabine and nab-paclitaxel chemotherapy. This regulatory clearance allows the company to market and sell the device in European markets for this indication. The approval references guideline recommendations to accommodate variations in how gemcitabine and nab-paclitaxel are used across different European countries.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 1, 2026 · How we verify